A case of subclinical hypothyroidism developing marked pleural effusions and peripheral edema with elevated vascular endothelial growth factor

Endocrine Journal

Volumn 54, Issue 4, 2007, Pages 577-584

  Hataya, Yuji ^a,b   Akamizu, Takashi ^c   Kanamoto, Naotetsu ^a   Moriyama, Kenji ^a   Shimatsu, Akira ^d   Nakao, Kazuwa ^a  

^a KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b SHIZUOKA CITY SHIMIZU HOSPITAL   (Japan)

^c KYOTO UNIVERSITY HOSPITAL   (Japan)

^d NATIONAL HOSPITAL ORGANIZATION KYOTO MEDICAL CENTER   (Japan)

Author keywords

Estradiol; Hypothyroidism; Pleural effusion; Primary myxedema; VEGF

Indexed keywords

THYROID HORMONE; THYROTROPIN; VASCULOTROPIN;

AGED; ANAMNESIS; ARTICLE; CASE REPORT; CLINICAL EXAMINATION; DISEASE ASSOCIATION; DISEASE COURSE; FEMALE; HORMONE BLOOD LEVEL; HORMONE SUBSTITUTION; HUMAN; HYPOTHYROIDISM; LABORATORY TEST; PERIPHERAL EDEMA; PHYSICAL EXAMINATION; PLEURA EFFUSION;

AGED; EDEMA; HUMANS; HYPOTHYROIDISM; MALE; PLEURAL EFFUSION; SEVERITY OF ILLNESS INDEX; THYROID HORMONES; THYROTROPIN; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 34548664815     PISSN: 09188959     EISSN: 13484540     Source Type: Journal    
DOI: 10.1507/endocrj.K06-114     Document Type: Article

References (39)

1. McDermott MT, Ridgway EC (2001) Subclinical hypothyroidism is mild thyroid failure and should be treated. J Clin Endocrinol Metab 86: 4585-4590.
2. Chu JW, Crapo LM (2001) The treatment of subclinical hypothyroidism is seldom necessary. J Clin Endocrinol Metab 86: 4591-4599.
3. Surks MI, Ortiz E, Daniels GH, Sawin CT, Col NF, Cobin RH, Franklyn JA, Hershman JM, Burman KD, Denke MA, Gorman C, Cooper RS, Weissman NJ (2004) Subclinical thyroid disease: scientific review and guidelines for diagnosis and management. JAMA 291: 228-238.
4. Meier C, Trittibach P, Guglielmetti M, Staub JJ, Muller B (2003) Serum thyroid stimulating hormone in assessment of severity of tissue hypothyroidism in patients with overt primary thyroid failure: cross sectional survey. BMJ 326: 311-312.
5. Lindsay RS, Toft AD (1997) Hypothyroidism. Lancet 349: 413-417.
6. Gottehrer A, Roa J, Stanford GG, Chernow B, Sahn SA (1990) Hypothyroidism and pleural effusions. Chest 98: 1130-1132.
7. Lange K (1944) Capillary permeability in myxedema. Am J Med Sci 208: 5-15.
8. Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N (1989) Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 246: 1306-1309.
9. Keck PJ, Hauser SD, Krivi G, Sanzo K, Warren T, Feder J, Connolly DT (1989) Vascular permeability factor, an endothelial cell mitogen related to PDGF. Science 246: 1309-1312.
10. Ferrara N, Carver-Moore K, Chen H, Dowd M, Lu L, O'Shea KS, Powell-Braxton L, Hillan KJ, Moore MW (1996) Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature 380: 439-442.
11. Kim KJ, Li B, Winer J, Armanini M, Gillett N, Phillips HS, Ferrara N (1993) Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 362: 841-844.
12. Senger DR, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VS, Dvorak HF (1983) Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 219: 983-985.
13. Lobb RR, Key ME, Alderman EM, Fett JW (1985) Partial purification and characterization of a vascular permeability factor secreted by a human colon adenocarcinoma cell line. Int J Cancer 36: 473-478.
14. Watanabe O, Arimura K, Kitajima I, Osame M, Maruyama I (1996) Greatly raised vascular endothelial growth factor (VEGF) in POEMS syndrome. Lancet 347: 702.
15. MuClure N, Healy DL, Rogers PA, Sullivan J, Beaton L, Haning RV Jr, Connolly DT, Robertson DM (1994) Vascular endothelial growth factor as capillary permeability agent in ovarian hyperstimulation syndrome. Lancet 344: 235-236.
16. Baker PN, Krasnow J, Roberts JM, Yeo KT (1995) Elevated serum levels of vascular endothelial growth factor in patients with preeclampsia. Obstet Gynecol 86: 815-821.
17. Emoto M, Anno T, Sato Y, Tanabe K, Okuya S, Tanizawa Y, Matsutani A, Oka Y (2001) Troglitazone treatment increases plasma vascular endothelial growth factor in diabetic patients and its mRNA in 3T3-L1 adipocytes. Diabetes 50: 1166-1170.
18. Dispenzieri A, Kyle RA, Lacy MQ, Rajkumar SV, Therneau TM, Larson DR, Greipp PR, Witzig TE, Basu R, Suarez GA, Fonseca R, Lust JA, Gertz MA (2003) POEMS syndrome: definitions and long-term outcome. Blood 10: 2496-2506.
19. Brown SD, Brashear RE, Schnute RB (1983) Pleural effusion in a young woman with myxedema. Arch Intern Med 143: 1458-1460.
20. Zulewski H, Muller B, Exer P, Miserez AR, Staub JJ (1997) Estimation of tissue hypothyroidism by a new clinical score: evaluation of patients with various grades of hypothyroidism and controls. J Clin Endocrinol Metab 82: 771-776.
21. Van den Berghe G, de Zegher F, Veldhuis JD, Wouters P, Gouwy S, Stockman W, Weekers F, Schetz M, Lauwers P, Bouillon R, Bowers CY (1997) Thyrotrophin and prolactin release in prolonged critical illness: dynamics of spontaneous secretion and effects of growth hormone-secretagogues. Clin Endocrinol (Oxf) 47: 599-612.
22. Parving HH, Hansen JM, Nielsen SL, Rossing N, Munck O, Lassen NA (1979) Mechanisms of edema formation in myxedema-increased protein extravasation and relatively slow lymphatic drainage. N Engl J Med 301: 460-465.
23. Ferrara N, Houck K, Jakeman L, Leung DW (1992) Molecular and biological properties of the vascular endothelial growth factor family of proteins. Endocr Rev 13: 18-32.
24. Sato K, Yamazaki K, Shizume K, Kanaji Y, Obara T, Ohsumi K, Demura H, Yamaguchi S, Shibuya M (1995) Stimulation by thyroid-stimulating hormone and Grave's immunoglobulin G of vascular endothelial growth factor mRNA expression in human thyroid follicles in vitro and flt mRNA expression in the rat thyroid in vivo. J Clin Invest 96: 1295-1302.
25. Soh EY, Duh QY, Sobhi SA, Young DM, Epstein HD, Wong MG, Garcia YK, Min YD, Grossman RF, Siperstein AE, Clark OH (1997) Vascular endothelial growth factor expression is higher in differentiated thyroid cancer than in normal or benign thyroid. J Clin Endocrinol Metab 82: 3741-3747.
26. Viglietto G, Romano A, Manzo G, Chiappetta G, Paoletti I, Califano D, Galati MG, Mauriello V, Bruni P, Lago CT, Fusco A, Persico MG (1997) Upregulation of the angiogenic factors PlGF, VEGF, and their receptors (Flt-1, Flk-1/KDR) by TSH in cultured thyrocytes and in the thyroid gland of thiouracil-fed rats suggest a TSH-dependent paracrine mechanism for goiter hypervascularization. Oncogene 15: 2687-2698.
27. Hoffmann S, Hofbauer LC, Scharrenbach V, Wunderlich A, Hassan I, Lingelbach S, Zielke A (2004) Thyrotropin (TSH)-induced production of vascular endothelial growth factor in thyroid cancer cells in vitro: evaluation of TSH signal transduction and of angiogenesis-stimulating growth factors. J Clin Endocrinol Metab 89: 6139-6145.
28. Klein M, Brunaud L, Muresan M, Barbe F, Marie B, Sapin R, Vignaud JM, Chatelin J, Angioi-Duprez K, Zarnegar R, Weryha G, Duprez A (2006) Recombinant human thyrotropin stimulates thyroid angiogenesis in vivo. Thyroid 16: 531-536.
29. Iitaka M, Miura S, Yamanaka K, Kawasaki S, Kitahama S, Kawakami Y, Kakinuma S, Oosuga I, Wada S, Katayama S (1998) Increased serum vascular endothelial growth factor levels and intrathyroidal vascular area in patients with Graves' disease and Hashimoto's thyroiditis. J Clin Endocrinol Metab 83: 3908-3912.
30. Miyagi E, Katoh R, Li X, Lu S, Suzuki K, Maeda S, Shibuya M, Kawaoi A (2001) Thyroid stimulating hormone downregulates vascular endothelial growth factor expression in FRTL-5 cells. Thyroid 11: 539-543.
31. Sorvillo F, Mazziotti G, Carbone A, Piscopo M, Rotondi M, Cioffi M, Musto P, Biondi B, Iorio S, Amato G, Carella C (2003) Recombinant human thyrotropin reduces serum vascular endothelial growth factor levels in patients monitored for thyroid carcinoma even in the absence of thyroid tissue. J Clin Endocrinol Metab 88: 4818-4822.
32. Tuttle RM, Fleisher M, Francis GL, Robbins RJ (2002) Serum vascular endothelial growth factor levels are elevated in metastatic differentiated thyroid cancer but not increased by short-term TSH stimulation. J Clin Endocrinol Metab 87: 1737-1742.
33. Schmid C, Brandle M, Zwimpfer C, Zapf J, Wiesli P (2004) Effect of thyroxine replacement on creatinine, insulin-like growth factor 1, acid-labile subunit, and vascular endothelial growth factor. Clin Chem 50: 228-231.
34. Ridgway EC, Longcope C, Maloof F (1975) Metabolic clearance and blood production rates of estradiol in hyperthyroidism. J Clin Endocrinol Metab 41: 491-497.
35. Longcope C, Abend S, Braverman LE, Emerson CH (1990) Androstenedione and estrone dynamics in hypothyroid women. J Clin Endocrinol Metab 70: 903-907.
36. Hyder SM, Nawaz Z, Chiappetta C, Stancel GM (2000) Identification of functional estrogen response elements in the gene coding for the potent angiogenic factor vascular endothelial growth factor. Cancer Res 60: 3183-3190.
37. Agrawal R, Prelevic G, Conway GS, Payne NN, Ginsburg J, Jacobs HS (2000) Serum vascular endothelial growth factor concentrations in postmenopausal women: the effect of hormone replacement therapy. Fertil Steril 73: 56-60.
38. Zacharieva S, Atanassova I, Kirilov G, Kalinov K, Shigarminova R, Nachev E, Aslanova N (2002) Effect of transdermal estrogen therapy on some vasoactive humoral factors and 24-h ambulatory blood pressure in normotensive postmenopausal women. Climacteric 5: 293-299.
39. Christodoulakos G, Lambrinoudaki I, Panoulis C, Papadias C, Sarandakou A, Liakakos T, Alexandrou A, Creatsas G (2004) Effect of hormone therapy, tibolone and raloxifene on circulating vascular endothelial growth factor in Greek postmenopausal women. Eur J Endocrinol 151: 187-192.